![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
E Meller and K Bohmaker
Millhauser Laboratories, Department of Psychiatry, New York University Medical Center, New York.
Treatment of rats with the serotonin 5-HT1A agonist 8-hydroxy-2-(di-n- propylamino)tetralin (8-OH-DPAT, 1 mg/kg s.c.) markedly elevated plasma levels of corticosterone (CORT), adrenocorticotropic hormone (ACTH) and prolactin (PRL); the levels of growth hormone were unaffected. Pretreatment with the irreversible receptor antagonist N-ethoxycarbonyl- 2-ethoxy-1,2-dihydroquinoline (EEDQ, 6 mg/kg s.c.) greatly attenuated the increase in plasma CORT produced by 8-OH-DPAT (0.3 mg/kg s.c.). Prevention of EEDQ-induced 5-HT1A receptor inactivation by prior treatment with the reversible mixed 5-HT1A/beta-adrenergic antagonist (+/-)pinodolol (30 mg/kg s.c.) blocked the reduction of the CORT response to 8-OH-DPAT. In contrast, prevention of EEDQ-induced inactivation of 5-HT2, alpha-1- and alpha-2-adrenergic and D1 and D2 dopamine receptors by a cocktail of selective antagonists of these receptors did not block the attenuation of the CORT response to 8-OH- DPAT. Dose-response curves were obtained for 8-OH-DPAT (0.01-3 mg/kg s.c.)-induced elevation of plasma CORT, ACTH and PRL after treatment (24 hr earlier) with vehicle or EEDQ (6 mg/kg s.c.) and analyzed for the extent of receptor reserve. Whereas substantial receptor reserves were observed for the 8-OH-DPAT rise in plasma CORT (80%) and ACTH (50%), no receptor reserve was seen for the increase in plasma PRL. The results are discussed with regard to potential differences in the receptors, G proteins, effectors and/or stoichiometric relationships between these components of the signal transduction pathway, leading to elevation of these plasma hormones after treatment with 8-OH-DPAT.
This article has been cited by other articles:
|
|
 |
|
  Y. Zhang, T. S. Gray, D. N. D'Souza, G. A. Carrasco, K. J. Damjanoska, B. Dudas, F. Garcia, G. M. Zainelli, N. R. Sullivan Hanley, G. Battaglia, et al. Desensitization of 5-HT1A Receptors by 5-HT2A Receptors in Neuroendocrine Neurons in Vivo J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 59 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, D. D'Souza, D. K. Raap, F. Garcia, G. Battaglia, N. A. Muma, and L. D. Van de Kar Characterization of the Functional Heterologous Desensitization of Hypothalamic 5-HT1A Receptors after 5-HT2A Receptor Activation J. Neurosci., October 15, 2001; 21(20): 7919 - 7927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. V. d. Kar, Q. Li, T. M. Cabrera, M. S. Brownfield, and G. Battaglia Alterations in 8-Hydroxy-2-(dipropylamino)tetralin-Induced Neuroendocrine Responses after 5,7-Dihydroxytryptamine-Induced Denervation of Serotonergic Neurons J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 256 - 262. [Abstract] [Full Text]
|
|
|
|
|
|
J. De Vry, R. Schohe-Loop, H.-G. Heine, J. M. Greuel, F. Mauler, B. Schmidt, H. Sommermeyer, and T. Glaser Characterization of the Aminomethylchroman Derivative BAY × 3702 as a Highly Potent 5-Hydroxytryptamine1A Receptor Agonist J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 1082 - 1094. [Abstract] [Full Text]
|
|
|
|
|
|
Q. Li, N. A. Muma, G. Battaglia, and L. D. Van De Kar A Desensitization of Hypothalamic 5-HT1A Receptors by Repeated Injections of Paroxetine: Reduction in the Levels of Gi and Go Proteins and Neuroendocrine Responses, but Not in the Density of 5-HT1A Receptors J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1581 - 1590. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
